Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 4/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 4/20 | 0.37 |
| ▸ | CCND1 | P24385 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14876293 | 0.88 | TYMS (0.49) | TYMSDHFR | |
| SCHEMBL18351112 | 0.88 | MAPK1 (0.50) | MAPK1TYMSADORA3PARP1CDK4 | |
| SCHEMBL18351120 | 0.83 | MAPK1 (0.52) | MAPK1TYMSADORA3PARP1CYP1A2 | |
| SCHEMBL18351088 | 0.80 | MAPK1 (0.55) | MAPK1TYMSADORA3PARP1PIM1 | |
| SCHEMBL18351113 | 0.79 | MAPK1 (0.51) | MAPK1TYMSADORA3PARP1CYP1A2 | |
| SCHEMBL18351114 | 0.79 | MAPK1 (0.48) | MAPK1TYMSADORA3PARP1CDK4 | |
| SCHEMBL18351115 | 0.79 | PARP1 (0.48) | MAPK1TYMSADORA3PARP1CDK4 | |
| SCHEMBL18351118 | 0.79 | MAPK1 (0.48) | MAPK1TYMSADORA3PARP1PIM1 | |
| SCHEMBL18351131 | 0.78 | MAPK1 (0.45) | MAPK1TYMSADORA3PARP1CYP1A2 | |
| SCHEMBL18351107 | 0.78 | MAPK1 (0.45) | MAPK1TYMSADORA3PARP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | F. HOFFMAN-LA ROCHE LTD | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | TTR, TYMP, TPMT | MAPK1 2142/4885TYMS 20/4885ADORA3 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.